Shannon Ouimet
Family · Sterling Heights, MINPI 1386206431
Payments from drug & device makers
Across 170 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$685
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$384
- Amgen$357
- AstraZeneca$275
- Lilly USA, LLC$259
- Boehringer Ingelheim$173
- plus $919 from 22 others
What the payments were for
- Food & beverage$3,052100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $685 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $384 |
| Amgen | 20 | $357 |
| AstraZeneca | 18 | $275 |
| Lilly USA, LLC | 16 | $259 |
| Boehringer Ingelheim | 8 | $173 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $132 |
| GSK | 7 | $115 |
| Pfizer | 7 | $113 |
| Novo Nordisk | 4 | $65 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $47 |
| Exact Sciences | 2 | $46 |
| Shield Therapeutics Inc | 3 | $42 |
| Merck | 2 | $40 |
| Bayer | 2 | $38 |
| Tolmar, Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Alvogen Inc | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Halozyme Inc | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Almatica Pharma LLC | 1 | $12 |
| Nestle Healthcare Nutrition Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,052 in reported general payments places this provider in the 85th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $58,737 |
| OzempicSemaglutide | 41 | $53,627 |
| JardianceEmpagliflozin | 60 | $51,639 |
| EliquisApixaban | 37 | $27,419 |
| TrulicityDulaglutide | 23 | $22,163 |
| VraylarCariprazine Hcl | 14 | $19,575 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $16,344 |
| RybelsusSemaglutide | 18 | $16,240 |
| FarxigaDapagliflozin Propanediol | 20 | $15,613 |
| UbrelvyUbrogepant | 16 | $15,290 |
| XareltoRivaroxaban | 16 | $13,943 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $11,769 |
| EntrestoSacubitril/Valsartan | 14 | $9,326 |
| VascepaIcosapent Ethyl | 18 | $7,221 |
| MyrbetriqMirabegron | 13 | $7,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $115 | $86,850127 claims |
| Novo NordiskOzempic, Rybelsus | $65 | $69,86759 claims |
| Boehringer IngelheimJardiance | $173 | $51,63960 claims |
| AbbVieVraylar, Ubrelvy | $685 | $34,86430 claims |
| PfizerEliquis | $113 | $27,41937 claims |
| Lilly USA, LLCTrulicity | $259 | $22,16323 claims |
| AstraZenecaFarxiga, Symbicort | $275 | $20,20640 claims |
| Johnson & JohnsonXarelto | $19 | $13,94316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,657 family providers in Michigan.
Other family in Sterling Heights
- Simona DenkovskiSterling Heights$11K
- Brittany SharpSterling Heights$10K
- Darlene BrownSterling Heights$9K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.